Valuation: Adaptive Biotechnologies Corporation

Market Cap 4.23B 3.78B 3.51B 3.19B 6.03B 409B 6.06B 42.27B 16.56B 209B 15.88B 15.53B 669B P/E 2026 *
-48.8x
P/E 2027 * -159x
Enterprise Value 4.05B 3.62B 3.37B 3.06B 5.79B 392B 5.81B 40.54B 15.89B 200B 15.23B 14.89B 642B EV / Sales 2026 *
13.8x
EV / Sales 2027 * 11.2x
Free-Float
97.94%
Yield 2026 *
-
Yield 2027 * -
1 day+1.53%
1 week-6.56%
Current month-8.34%
1 month+9.33%
3 months+25.78%
6 months+107.11%
Current year+63.12%
1 week 25.12
Extreme 25.12
30.74
1 month 23.96
Extreme 23.965
30.74
Current year 12
Extreme 12
30.74
1 year 12
Extreme 12
30.74
3 years 2.28
Extreme 2.28
30.74
5 years 2.28
Extreme 2.28
37.55
10 years 2.28
Extreme 2.28
71.25
Manager TitleAgeSince
Chief Executive Officer 51 2009-09-07
Director of Finance/CFO 42 2024-04-07
President 54 2018-01-31
Director TitleAgeSince
Chairman 51 -
Director/Board Member 63 2013-01-31
Director/Board Member 70 2013-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
10/8/26 Exercice

Chairperson

35,643 0.0223%
10/6/26 Sell

Executive/Senior Manager

-6,444 0.0040%
10/5/26 Exercice

Chairperson

35,643 0.0223%
Change 5-day change 1-year change 3-year change Capi.($)
+1.53%-6.56%+74.62%+435.15% 4.23B
-2.59%-5.70%+50.69%+86.86% 70.61B
+3.23%-10.67%+6.27%+53.70% 51.01B
+1.56%+1.17%+8.49%+31.81% 48.1B
+0.39%+0.65%+31.14%+28.97% 42.78B
+0.87%-8.17%+293.37%+642.41% 40.67B
+1.24%-1.01%+10.74%+100.64% 40.3B
-2.13%-1.64%+8.63%+46.88% 30.59B
-0.46%-1.28%+42.23%+20.34% 28.16B
+5.32%+0.06%-5.00%-12.78% 24.36B
Average +0.90%-3.05%+52.12%+143.40% 38.08B
Weighted average by Cap. +0.57%-2.98%+51.61%+119.12%

Financials

2026 *2027 *
Net sales 293M 262M 244M 222M 419M 28.4B 420M 2.93B 1.15B 14.48B 1.1B 1.08B 46.46B 359M 321M 298M 271M 513M 34.77B 515M 3.59B 1.41B 17.72B 1.35B 1.32B 56.88B
Net income -85.55M -76.41M -71.08M -64.65M -122M -8.28B -123M -855M -335M -4.22B -321M -314M -13.55B -26.13M -23.34M -21.71M -19.75M -37.29M -2.53B -37.45M -261M -102M -1.29B -98.14M -96M -4.14B
Net Debt -173M -155M -144M -131M -247M -16.75B -248M -1.73B -678M -8.54B -650M -636M -27.41B -217M -194M -181M -164M -310M -21.03B -311M -2.17B -851M -10.72B -816M -798M -34.41B
Projected Income Statement - Annual - Adaptive Biotechnologies Corporation
Logo Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
Employees
624
Date Price Change Volume
26-10-09 US$26.49 +1.53% 1,525,258
26-10-08 US$26.09 -0.72% 2,646,924
26-10-07 US$26.28 -2.30% 2,120,225
26-10-06 US$26.90 -9.85% 2,533,775
26-10-05 US$29.84 +5.26% 1,425,150
Trader
Investor
Global
Quality
ESG MSCI
BBB
Ratings Surperformance© - Adaptive Biotechnologies Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
26.49USD
Average target price
28.31USD
Spread / Average Target
+6.88%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Adaptive Biotechnologies Corporation
  1. Stock Market
  2. Stocks
  3. ADPT Stock